acceleronpharma.com acceleronpharma.com

acceleronpharma.com

Acceleron Pharma

INVESTORS & MEDIA. Oral Presentation: Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplas. Our discovery platform is an exceptionally rich source of novel protein therapies to treat patients with life-threatening and debilitating conditions.

http://www.acceleronpharma.com/

WEBSITE DETAILS
SEO
PAGES
SIMILAR SITES

TRAFFIC RANK FOR ACCELERONPHARMA.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

August

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Monday

TRAFFIC BY CITY

CUSTOMER REVIEWS

Average Rating: 3.8 out of 5 with 6 reviews
5 star
1
4 star
3
3 star
2
2 star
0
1 star
0

Hey there! Start your review of acceleronpharma.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

Desktop Preview Tablet Preview Mobile Preview

LOAD TIME

4.9 seconds

CONTACTS AT ACCELERONPHARMA.COM

Acceleron Pharma

24 Em●●●●●treet

Cam●●●dge , MA, 02139

US

1.61●●●●2220
mw●●●@isdsi.com

View this contact

Acceleron Pharma

Acceleron Pharma

24 Em●●●●●treet

Cam●●●dge , MA, 02139

US

1.61●●●●2220
mm●●●●●●@acceleronpharma.com

View this contact

Acceleron Pharma

Acceleron Pharma

24 Em●●●●●treet

Cam●●●dge , MA, 02139

US

1.61●●●●2220
mm●●●●●●@acceleronpharma.com

View this contact

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

DOMAIN REGISTRATION INFORMATION

REGISTERED
2003 December 21
UPDATED
2014 March 25
EXPIRATION
EXPIRED REGISTER THIS DOMAIN

BUY YOUR DOMAIN

Network Solutions®

DOMAIN AGE

  • 20

    YEARS

  • 4

    MONTHS

  • 27

    DAYS

NAME SERVERS

1
ns1.p30.dynect.net
2
ns2.p30.dynect.net
3
ns3.p30.dynect.net
4
ns4.p30.dynect.net

REGISTRAR

NETWORK SOLUTIONS, LLC.

NETWORK SOLUTIONS, LLC.

WHOIS : whois.networksolutions.com

REFERRED : http://networksolutions.com

CONTENT

SCORE

6.2

PAGE TITLE
Acceleron Pharma | acceleronpharma.com Reviews
<META>
DESCRIPTION
INVESTORS & MEDIA. Oral Presentation: Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplas. Our discovery platform is an exceptionally rich source of novel protein therapies to treat patients with life-threatening and debilitating conditions.
<META>
KEYWORDS
1 acceleron
2 our company
3 management
4 board of directors
5 careers
6 partners
7 tgf β superfamily
8 sotatercept
9 luspatercept
10 dalantercept
CONTENT
Page content here
KEYWORDS ON
PAGE
acceleron,our company,management,board of directors,careers,partners,tgf β superfamily,sotatercept,luspatercept,dalantercept,publications,transforming,research/,medicine/,lives,recent news,press release,view full,recent publications,anemia,cancer,site map
SERVER
Apache
CONTENT-TYPE
utf-8
GOOGLE PREVIEW

Acceleron Pharma | acceleronpharma.com Reviews

https://acceleronpharma.com

INVESTORS & MEDIA. Oral Presentation: Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplas. Our discovery platform is an exceptionally rich source of novel protein therapies to treat patients with life-threatening and debilitating conditions.

SUBDOMAINS

investor.acceleronpharma.com investor.acceleronpharma.com

Acceleron Pharma » Investors

Aug 14, 2015 at 4:00 PM ET. Intraday data provided by eSignal. At Acceleron, we aim to transform the lives of people suffering from cancer and orphan diseases by discovering and developing innovative therapies. Acceleron scientists have world-leading expertise in developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily. Since our founding in 2004, Acceleron has brought multiple distinct, internally-discovered, developed and manufactured products. RECENT RELEASES View all.

INTERNAL PAGES

acceleronpharma.com acceleronpharma.com
1

Acceleron Pharma » Posters, Presentations & Publications

http://www.acceleronpharma.com/publications

POSTERS, PRESENTATIONS & PUBLICATIONS. Jul 8, 2016. ACE-083, A Locally-Acting Muscle Agent, Increases Muscle Volume In Healthy Volunteers. 14th International Congress on Neuromuscular Diseases; July 8, 2016. Jun 12, 2016. Luspatercept Decreases Transfusion Burden and Liver Iron Concentration in Regularly Transfused Adults with Beta-Thalassemia. 21st Congress of the European Hematology Association; June 9-12, 2016. Jun 11, 2016. Jun 10, 2016. Jun 10, 2016. Jun 10, 2016. Apr 2, 2016. ACE-083, a Locally-Act...

2

Acceleron Pharma » Careers

http://www.acceleronpharma.com/our-company/careers

POSTERS, PRESENTATIONS & PUBLICATIONS. Associate Director, Clinical Operations. Manager/Senior Manager, Clinical Quality Assurance. Research Associate, Bioanalytical Development. Scientist, Preclinical Pharmacology. Scientist, Protein Purification. Sr Research Associate, Protein Purification - Discovery. Acceleron Pharma is an equal opportunity employer. Acceleron Pharma only hires individuals that are legally authorized to work in the United States. Life Insurance (100% company paid), including dependen...

3

Acceleron Pharma » Our Company

http://www.acceleronpharma.com/our-company

POSTERS, PRESENTATIONS & PUBLICATIONS. ACE-083, A Locally-Acting Muscle Agent, Increases Muscle Volume In Healthy Volunteers. 14th International Congress on Neuromuscular Diseases. Luspatercept Decreases Transfusion Burden and Liver Iron Concentration in Regularly Transfused Adults with Beta-Thalassemia. 21st Congress . Luspatercept Increases Hemoglobin, Reduces Liver Iron Concentration and Improves Quality of Life in Non-Transfusion Dependent Adults with B.

4

Acceleron Pharma » Pipeline

http://www.acceleronpharma.com/products

POSTERS, PRESENTATIONS & PUBLICATIONS. Acceleron is developing first-in-class therapies intended to transform patients’ lives. We focus on products with unique properties that can provide meaningful advantages over existing treatments, or that can address diseases for which no approved therapies exist. We have built a rich pipeline of biologic therapies and have four internally developed programs in clinical trials.

5

Acceleron Pharma » Dalantercept

http://www.acceleronpharma.com/products/dalantercept

POSTERS, PRESENTATIONS & PUBLICATIONS. The DART Study Part 1: Updated Results of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. International Kidney Cancer Symposium. The DART Study Part 2: A Phase 2 Randomized, Double-Blind Study of Dalantercept plus Axitinib Compared to Placebo plus Axitinib in Patients. For Advanced / Metastatic Cancer. Dalantercept (ACE-041) is an investigational protein therapeutic that inhibits angiogenesis by preventing BMP9 and BMP10, proteins in the TGF-β superfami...

UPGRADE TO PREMIUM TO VIEW 8 MORE

TOTAL PAGES IN THIS WEBSITE

13

LINKS TO THIS WEBSITE

oho-projects.blogspot.com oho-projects.blogspot.com

OHO: The Digital Agency: Acceleron Pharma Joins the OHO Ranks Looking to Extend Recruitment AdvertisingBoston Web Design, Graphic Design, Web Applications, Zipcar, Jonathan Edwards Center, ICA, Institute of Contemporary Art, Travel and Tourism Web Sites, R

http://oho-projects.blogspot.com/2007/10/acceleron-looks-to-enhance-recruitment.html

OHO: The Digital Agency. Award-Winning Creative Web Applications Life Science Recruitment Advertising. Friday, October 12, 2007. Acceleron Pharma Joins the OHO Ranks Looking to Extend Recruitment Advertising. Has signed with OHO this week becoming our sixth life sciences client along with Synta Pharmaceuticals and Vertex Pharmaceuticals. OHO will be completing a new career fair booth for Acceleron and planning a print advertising strategy. Labels: life science recruitment advertising.

hrbiotechconnect.com hrbiotechconnect.com

HR BioTech Connect » Members

http://hrbiotechconnect.com/members

HR Biotech Connect Home. April 2017 Event with Radford – Submit Your Questions for our Speakers. Building a Mission-Driven Organization: May 16th. Building and Maintaining a Strong Company Culture. December 2014: Spotlight on the Changing OFCCP Regulations. February 2014: Building High Performance Teams. February 2015: Insights into Personal and Team Communication. HR Roundtable Meeting: April 18th. June 2014 Meeting: Responding to Your CFO: Self-Funding and ACA Readiness. BioTech Journey through the Pha...

openicon.blogspot.com openicon.blogspot.com

Dissecting the Bull: July 2015

http://openicon.blogspot.com/2015_07_01_archive.html

Reporting about and analyzing technology stocks. Sunday, July 26, 2015. Buying flurry: Dot Hill, Star Bulk, Ocata Therapeutics, Acceleron, Biogen. It is earnings season so I am very busy, so I am behind in updating followers on my trades. If you want to read the notes I make on the analyst conferences of the stocks I follow, you can find a list of the stocks with links at: Meyers Analyst Conference List. I only sold once stock lately, a bit of my Celgene. I also added shares of Dot Hill. For Seeking Alph...

investor.acceleronpharma.com investor.acceleronpharma.com

Acceleron Pharma » Historic Stock Lookup

http://investor.acceleronpharma.com/stocklookup.cfm

POSTERS, PRESENTATIONS & PUBLICATIONS. Todd James, IRC. Senior Director, Investor Relations and Corporate Communications. Week of October 31, 2016. Oct 31, 2016. Nov 1, 2016. Year End Stock Prices.

avalon-ventures.com avalon-ventures.com

Our Investments - Avalon Ventures

http://www.avalon-ventures.com/our-investments

Middot; Company Website. Middot; Company Website. Middot; Company Website. Middot; Company Website. Middot; Company Website. Middot; Company Website. Middot; Company Website. Middot; Company Website. Middot; Company Website. Middot; Company Website. Avelas Biosciences, Inc. Middot; Company Website. Middot; Company Website. Middot; Company Website. Middot; Company Website. Middot; Company Website. Middot; Company Website. Caliper Life Sciences, Inc. Middot; Company Website. Cambrios Technologies, Corp.

biotechpress.supbiotech.fr biotechpress.supbiotech.fr

BiotechPress, l'actualité des biotechnologies par les étudiants de Sup'Biotech

http://biotechpress.supbiotech.fr/sante

Ils font avancer la recherche. Les secteurs des biotechs. Formation labellisée par I.A.R. Débouchés après la PAES. Recherche partenariale, LRPIA. Pôle sciences humaines et. Vie associative and culturelle. Se loger, se restaurer. Remise des diplômes. L'avenir est aux nouveaux métiers de la biotechnologie. Vers une alternative au don de sang. Le don de sang ne prend pas de vacances. Ce rappel estival de l'Etablissement Français du sang (EFS). Pour réaliser cette transfusion, l'équipe de Luc Douay a utilisé...

kalynndibble.blogspot.com kalynndibble.blogspot.com

Cruising for a Bruising: Hope for a Therapeutic Drug to Treat MD

http://kalynndibble.blogspot.com/2010/08/hope-for-therapeutic-drug-to-treat-md.html

Cruising for a Bruising. Tuesday, August 10, 2010. Hope for a Therapeutic Drug to Treat MD. Dr Kathryn Wagner was one of the speakers who attended the FSH Society International Patient and Researcher Meeting in Las Vegas. (Which there will be more information on to come) She believes that ACE-031, made by Acceleron Pharma Inc., will be effective in FSHD. ACE-031 is a drug being developed to increase muscle mass and strength to treat neuromuscular diseases. From the Accelron website. Thank you for sharing!

UPGRADE TO PREMIUM TO VIEW 98 MORE

TOTAL LINKS TO THIS WEBSITE

105

SOCIAL ENGAGEMENT



OTHER SITES

acceleronllc.net acceleronllc.net

Website Disabled

Sorry, the site you requested has been disabled.

acceleronlogistics.com acceleronlogistics.com

Acceleron Logistics

acceleronmedia.net acceleronmedia.net

Site Unavailable

This site is currently unavailable.

acceleronmotorsport.wordpress.com acceleronmotorsport.wordpress.com

@cceleron Motorsport | Competição e Desportos Motorizados Low-Cost

Competição e Desportos Motorizados Low-Cost. The WordPress.com stats helper monkeys prepared a 2013 annual report for this blog. Here’s an excerpt:. A San Francisco cable car holds 60 people. This blog was viewed about 1,400. Times in 2013. If it were a cable car, it would take about 23 trips to carry that many people. Click here to see the complete report. Filed under Última Hora! Mais vale um caneco na mão que dois a voar…. Não houve milagre nos Milagres…. Ricardo Trincadeiro fechou o pódio no 3º lugar...

acceleronomy.com acceleronomy.com

Acceleronomy

Last update: 9th. August, 2013.

acceleronpharma.com acceleronpharma.com

Acceleron Pharma

INVESTORS & MEDIA. Oral Presentation: Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplas. Our discovery platform is an exceptionally rich source of novel protein therapies to treat patients with life-threatening and debilitating conditions.

acceleronpharma.net acceleronpharma.net

Site not found · DreamHost

Well, this is awkward. The site you're looking for is not here. Is this your site?

acceleronpharma.org acceleronpharma.org

Site not found · DreamHost

Well, this is awkward. The site you're looking for is not here. Is this your site?

accelerons.com accelerons.com

Accelerons

acceleronservices.com acceleronservices.com

Acceleron Consulting Services, LLC

Acceleron Consulting Services, LLC. Moving your vision in the right direction. Powered by InstantPage® from GoDaddy.com. Want one?

acceleronslefficacite.com acceleronslefficacite.com

Small Business Marketing

Online купить ростов-на-дону индийская виагра. Online купить ростов-на-дону виагра таблетки. Online купить ростов-на-дону женская виагра. Online купить ростов-на-дону зибан. Online купить ростов-на-дону левитра. Online купить ростов-на-дону сиалис софт. Online купить ростов-на-дону сиалис. Guidance for small business owners to understand, manage and market online. Brings You Company at Top with SEO Experts. This entry was posted in Marketing. March 2, 2013. Legal services for small business owners. Small...